UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 12, 2015
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36279 |
|
75-3175693 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
1 Parrott Drive
Shelton, Connecticut |
|
06484 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code (203) 567-1500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2.):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. |
Results of Operations and Financial Condition. |
Cara Therapeutics, Inc. (the Company) issued
a press release on May 12, 2015 announcing its financial results for the first quarter ended March 31, 2015. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated by reference to this Item 2.02.
The information furnished pursuant to this Item 2.02 shall not be deemed
to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of
the Companys filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as
expressly set forth by specific reference in such a filing. Except as required by law, we undertake no duty or obligation to publicly update or revise the information so furnished.
Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press Release dated May 12, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
CARA THERAPEUTICS, INC. |
|
|
By: |
|
/s/ JOSEF SCHOELL |
|
|
Josef Schoell |
|
|
Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
Date: May 12, 2015
Exhibit 99.1
Cara Therapeutics Reports First Quarter 2015 Financial Results
- End-of-Phase 2 meeting with FDA informs Phase 3 clinical
development program for novel kappa opioid, I.V. CR845 -
-
- Conference call today at
4:30pm ET
SHELTON, CONN., May 12th, 2015 Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company
focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2015 and provided
an update on its Phase 3 program for I.V. CR845.
The first half of 2015 continues to be an important period for the Company as we work to finalize
and initiate our Phase 3 program for I.V. CR845, which offers the potential for post-operative pain relief without typical opioid side effects, said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
End-of-Phase 2 Meeting Overview
|
|
|
Based on discussions with the U.S. Food and Drug Administration (FDA), the Company currently anticipates the first trial of its I.V. CR845 Phase 3 Program to be a pivotal adaptive trial designed to meet FDA
criteria for an adequate and well-controlled clinical trial. The trial will evaluate several doses of I.V. CR845, administered both pre- and post-operatively, in patients undergoing abdominal laparoscopic surgery, including laparoscopic
hysterectomy. Cara expects to initiate the trial in the third quarter of 2015, with completion expected in 2016. |
|
|
|
The FDA provided guidance on optimum methodology to assess the impact of I.V. CR845 on postoperative nausea and vomiting. |
|
|
|
The FDA advised the Company that its non-clinical and toxicology packages appear adequate for NDA submission; CMC strategy deemed supportive of NDA submission. |
1
We look forward to initiating the first trial of our I.V. CR845 Phase 3 Program, said
Dr. Chalmers. Based on discussions at our End-of-Phase 2 meeting, we believe that our currently proposed trials will better position I.V. CR845 for the strongest possible regulatory submission. We were also encouraged by FDA guidance on
our non-clinical and toxicology packages and current CMC strategy.
During the first quarter of 2015, we also continued to execute on our
Phase 2 proof-of-concept study in uremic pruritus and expect to report top-line data from the trial in the second quarter of 2015, added Dr. Chalmers. Additionally, we have finalized the Phase 2 protocol for the oral formulation of
CR845 and expect to initiate that trial in the third quarter of 2015, with top-line data expected by year-end 2015.
First Quarter and Recent
Business/Corporate Highlights
|
|
|
Held End-of-Phase 2 meeting with the FDA. |
|
|
|
Presented data from human abuse liability study of I.V. CR845 in oral session at the 3rd Conference on the Therapeutic Potential of Kappa Opioids.
|
|
|
|
Hired Heads of Clinical Development and Clinical Operations. |
Expected Upcoming Milestones
|
|
|
Initiate I.V. CR845 Phase 3 Program in 3Q15 with pivotal adaptive trial in laparoscopic abdominal surgery, with two additional Phase 3 trials in laparoscopic hysterectomy and bunionectomy to begin in 1H16.
|
|
|
|
Report top-line efficacy data from the Phase 2 trial of I.V. CR845 in uremic pruritus in 2Q15. |
|
|
|
Initiate Phase 2 trial for Oral CR845 in OA (osteoarthritis) patients in 3Q15. |
|
|
|
Report top-line data from Phase 2 trial of Oral CR845 by the end of 2015. |
2
First Quarter 2015 Financial Results
Net Loss: Net loss was $4.7 million, or $0.21 per basic and diluted share, for the first quarter of 2015, compared to net loss of $3.4 million, or $0.22
per basic and diluted share for the same period of 2014.
Revenues: Collaborative revenue was $489,000 for the first quarter of 2015, compared to
$151,000 for the same period of 2014, comprising revenue that had been deferred upon entry into the license agreement with Maruishi Pharmaceutical Company Ltd. (Maruishi). Clinical compound revenue was $0 for the first quarter of 2015 compared to
$27,000 for the same period of 2014, from the sale of clinical compound to Maruishi.
Research and Development (R&D) Expenses: R&D expenses
were $3.4 million in the first quarter of 2015, compared to $2.2 million for the same period of 2014. The higher R&D expenses in the first quarter of 2015 were principally due to a net increase in direct preclinical studies and clinical trial
costs, an increase in consultant services in support of preclinical studies and clinical trials, and increases in payroll, recruiting and related costs, including stock option expense, associated with R&D personnel.
General and Administrative (G&A) Expenses: G&A expenses were $1.8 million in the first quarter of 2015, compared to $1.4 million in the same
period of 2014. The increase in the first quarter of 2015 was primarily due to increases in professional fees, public/investor relations costs, payroll and related costs, mostly due to increases in headcount, and directors and
officers insurance costs.
Interest Income: Interest income was $14,000 for the first quarter of 2015, compared to $22,000 for the same
period of 2014.
Cash Position: At March 31, 2015, cash and cash equivalents were $47.4 million, compared to $52.7 million at
December 31, 2014. The decrease was principally related to cash and cash equivalents used in operating activities during the first quarter of 2015.
Conference Call
Cara management will host a conference
call today at 4:30 p.m. ET to discuss first quarter 2015 financial results and provide a business update.
To participate in the conference call, please
dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 41947428. A live webcast of the call can be accessed under Events and Presentations in the News & Investors section of the Companys
website at www.CaraTherapeutics.com.
3
An archived webcast recording will be available on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is
a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of
product candidates that target the bodys peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain
therapeutics.
Forward-looking Statements
Statements
contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements
include statements concerning the expected timing for the Companys clinical trials and the reporting of clinical trial results, the acceptability to the FDA of the Companys proposed Phase 3 program for I.V. CR845, the potential results
of ongoing and planned clinical trials and future regulatory and development milestones for the Companys product candidates, and the potential for CR845 to provide a new therapeutic approach to treating uremic pruritus. Because such statements
are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics filings with the Securities and Exchange
Commission, including the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2014 and its other documents subsequently filed with or furnished to the Securities and Exchange
Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Financial tables follow
4
CARA THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2015 |
|
|
2014 |
|
|
|
|
Revenue: |
|
|
|
|
|
|
|
|
Collaborative revenue |
|
$ |
489 |
|
|
$ |
151 |
|
Clinical compound revenue |
|
|
|
|
|
|
27 |
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
489 |
|
|
|
178 |
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
3,385 |
|
|
|
2,201 |
|
General and administrative |
|
|
1,822 |
|
|
|
1,398 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
5,207 |
|
|
|
3,599 |
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(4,718 |
) |
|
|
(3,421 |
) |
|
|
|
Interest income |
|
|
14 |
|
|
|
22 |
|
|
|
|
|
|
|
|
|
|
Loss before benefit from income taxes |
|
|
(4,704 |
) |
|
|
(3,399 |
) |
|
|
|
Benefit from income taxes |
|
|
15 |
|
|
|
16 |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,689 |
) |
|
$ |
(3,383 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share: |
|
|
|
|
|
|
|
|
Basic and Diluted |
|
$ |
(0.21 |
) |
|
$ |
(0.22 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares: |
|
|
|
|
|
|
|
|
Basic and Diluted |
|
|
22,808,479 |
|
|
|
15,654,079 |
|
5
CARA THERAPEUTICS, INC.
BALANCE SHEETS
(in
thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
|
|
December 31, 2014 |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
47,422 |
|
|
$ |
52,663 |
|
Income tax receivable |
|
|
215 |
|
|
|
200 |
|
Prepaid expenses |
|
|
1,420 |
|
|
|
287 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
49,057 |
|
|
|
53,150 |
|
Property and equipment, net |
|
|
1,897 |
|
|
|
2,084 |
|
Restricted cash |
|
|
700 |
|
|
|
700 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
51,654 |
|
|
$ |
55,934 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
2,464 |
|
|
$ |
1,946 |
|
Deferred Revenue |
|
|
963 |
|
|
|
1,452 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
3,427 |
|
|
|
3,398 |
|
|
|
|
Deferred lease obligation |
|
|
803 |
|
|
|
874 |
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock |
|
|
|
|
|
|
|
|
Common stock |
|
|
23 |
|
|
|
23 |
|
Additional paid-in capital |
|
|
132,291 |
|
|
|
131,840 |
|
Accumulated deficit |
|
|
(84,890 |
) |
|
|
(80,201 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
47,424 |
|
|
|
51,662 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
51,654 |
|
|
$ |
55,934 |
|
|
|
|
|
|
|
|
|
|
Contacts
Jesse
Baumgartner, Stern Investor Relations, 212-362-1200
Annie Starr, 6 Degrees PR, 973-415-8838
6
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jul 2023 to Jul 2024